JP2009537606A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009537606A5 JP2009537606A5 JP2009511518A JP2009511518A JP2009537606A5 JP 2009537606 A5 JP2009537606 A5 JP 2009537606A5 JP 2009511518 A JP2009511518 A JP 2009511518A JP 2009511518 A JP2009511518 A JP 2009511518A JP 2009537606 A5 JP2009537606 A5 JP 2009537606A5
- Authority
- JP
- Japan
- Prior art keywords
- lower alkyl
- mono
- phenyl
- amino
- carboxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- -1 benzcycloalkyl Chemical group 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 125000002619 bicyclic group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 5
- 125000002950 monocyclic group Chemical group 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 102000050554 Eph Family Receptors Human genes 0.000 claims description 3
- 108091008815 Eph receptors Proteins 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000003373 pyrazinyl group Chemical class 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical class 0.000 claims 2
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- ZGBAJMQHJDFTQJ-DEOSSOPVSA-N bafetinib Chemical compound C1[C@@H](N(C)C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=NC=3)C(C)=CC=2)C=C1C(F)(F)F ZGBAJMQHJDFTQJ-DEOSSOPVSA-N 0.000 description 1
- 229950002365 bafetinib Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80318206P | 2006-05-25 | 2006-05-25 | |
| PCT/EP2007/055016 WO2007137981A1 (en) | 2006-05-25 | 2007-05-23 | Inhibitors of tyrosine kinases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013096740A Division JP2013189443A (ja) | 2006-05-25 | 2013-05-02 | チロシンキナーゼ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009537606A JP2009537606A (ja) | 2009-10-29 |
| JP2009537606A5 true JP2009537606A5 (enExample) | 2013-01-10 |
Family
ID=38255250
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009511518A Pending JP2009537606A (ja) | 2006-05-25 | 2007-05-23 | チロシンキナーゼ阻害剤 |
| JP2013096740A Pending JP2013189443A (ja) | 2006-05-25 | 2013-05-02 | チロシンキナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013096740A Pending JP2013189443A (ja) | 2006-05-25 | 2013-05-02 | チロシンキナーゼ阻害剤 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US8093259B2 (enExample) |
| JP (2) | JP2009537606A (enExample) |
| WO (1) | WO2007137981A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200840581A (en) * | 2007-02-28 | 2008-10-16 | Astrazeneca Ab | Novel pyrimidine derivatives |
| TW201006823A (en) * | 2008-07-14 | 2010-02-16 | Novartis Ag | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis |
| US20140080772A1 (en) * | 2012-09-06 | 2014-03-20 | The Board Of Regents Of The University Of Texas System | Treatments for melanoma |
| JP7057975B2 (ja) * | 2016-12-14 | 2022-04-21 | 国立大学法人信州大学 | 殺細胞効果を有するキメラ抗原受容体遺伝子改変リンパ球 |
| JP6944801B2 (ja) * | 2017-03-29 | 2021-10-06 | 株式会社Ｓｃｒｅｅｎホールディングス | ヒートローラおよびそれを備えた印刷装置 |
| TWI770624B (zh) | 2018-06-15 | 2022-07-11 | 漢達生技醫藥股份有限公司 | 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| EP1390385A4 (en) * | 2001-05-29 | 2004-11-24 | Sirna Therapeutics Inc | MODULATION OF DISEASES AND DISEASES OF THE FEMALE REPRODUCTION SYSTEM BASED ON NUCLEIC ACID |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| MXPA05012723A (es) * | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
| HUE034712T2 (hu) * | 2003-12-25 | 2018-02-28 | Nippon Shinyaku Co Ltd | Amidszármazék és gyógyszer |
| WO2005123104A2 (en) * | 2004-06-10 | 2005-12-29 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for the treatment of human cancer |
| GB0425035D0 (en) | 2004-11-12 | 2004-12-15 | Novartis Ag | Organic compounds |
| CN101203224B (zh) * | 2005-01-28 | 2010-11-03 | 诺瓦提斯公司 | 嘧啶基氨基苯甲酰胺在制备治疗对Tie-2激酶活性的调节有响应的疾病的药物中的用途 |
-
2007
- 2007-05-23 JP JP2009511518A patent/JP2009537606A/ja active Pending
- 2007-05-23 WO PCT/EP2007/055016 patent/WO2007137981A1/en not_active Ceased
- 2007-05-23 US US12/301,690 patent/US8093259B2/en not_active Expired - Fee Related
-
2013
- 2013-05-02 JP JP2013096740A patent/JP2013189443A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230116233A1 (en) | Compounds And Compositions As Protein Kinase Inhibitors | |
| JP2011530607A5 (enExample) | ||
| RU2315043C2 (ru) | Амидное производное, фармацевтическая композиция и терапевтические средства на его основе | |
| RU2012124811A (ru) | СПОСОБ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И ДРУГИХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ АКТИВНОСТЬЮ КИНАЗ Bcr-Abl, c-Kit, DDR1, DDR2, ИЛИ PDGF-R | |
| JP2020503299A5 (enExample) | ||
| JP2016514718A5 (enExample) | ||
| JP2008528467A5 (enExample) | ||
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| RU2012120901A (ru) | Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r | |
| JP2017535589A (ja) | ２−アミノピリミジン系化合物およびその薬物組成物と使用 | |
| US20130096149A1 (en) | Heteroaryl compounds and compositions as protein kinase inhibitors | |
| JP2019505595A5 (enExample) | ||
| JP2019505594A5 (enExample) | ||
| RU2018131766A (ru) | 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета | |
| RU2012147511A (ru) | Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза | |
| RU2011109078A (ru) | Лечение легочной артериальной гипертензии | |
| JP2009537606A5 (enExample) | ||
| RU2011105059A (ru) | Применение производных пиримидиламинобензамида для лечения фиброза | |
| JP2017536342A5 (enExample) | ||
| RU2008127264A (ru) | Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза | |
| RU2007132255A (ru) | Применение пиримидиламинобензамидов для лечения заболеваний, чувствительных к модуляции активности киназы tie-2 | |
| JP2020531485A5 (enExample) | ||
| RU2007144530A (ru) | Применение производных пиримидиламинобензамида для лечения системного мастоцитоза | |
| EP1893213B1 (en) | Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases | |
| US20250188075A1 (en) | Substituted heterocyclic csnk1 inhibitors |